Related references
Note: Only part of the references are listed.Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review
Fan-Shun Zhang et al.
ACTA PHARMACOLOGICA SINICA (2022)
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart et al.
CELL METABOLISM (2022)
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph et al.
CIRCULATION (2022)
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial
Dominik Dahl et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Wei Chen et al.
NATURE REVIEWS CARDIOLOGY (2022)
A GLP-1/glucagon (GCG)/CCK2 receptors tri-agonist provides new therapy for obesity and diabetes
Songfeng Zhao et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Oliver Schnell et al.
CARDIOVASCULAR DIABETOLOGY (2022)
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar et al.
NATURE MEDICINE (2022)
Impact of Cotadutide drug on patients with type 2 diabetes mellitus: a systematic review and meta-analysis
Mahmoud M. Ali et al.
BMC ENDOCRINE DISORDERS (2022)
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan et al.
FRONTIERS IN ENDOCRINOLOGY (2022)
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Ali A. Rizvi et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2022)
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda et al.
MOLECULES (2022)
What's preventing us from curbing the obesity crisis?
[Anonymous]
LANCET DIABETES & ENDOCRINOLOGY (2022)
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
Vanita R. Aroda et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2022)
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr et al.
MOLECULAR METABOLISM (2022)
The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
Yousef Alhindi et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr et al.
MOLECULAR METABOLISM (2022)
Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice
Stephan Sachs et al.
DIABETES OBESITY & METABOLISM (2021)
Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia
Maria Aguilar-Ballester et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min et al.
DIABETES THERAPY (2021)
GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism
Geke Aline Boer et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato et al.
LANCET (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs
Soren Ostergaard et al.
SCIENTIFIC REPORTS (2021)
Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide
Michele Schiavon et al.
DIABETES OBESITY & METABOLISM (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Proglucagon-Derived Peptides as Therapeutics
Ryan A. Lafferty et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
Yanyun Chen et al.
DIABETES (2021)
Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared with Insulin Degludec in Patients with Type 2 Diabetes (SURPASS-3)
Bernhard Ludvik et al.
DIABETES (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen et al.
EXPERT OPINION ON EMERGING DRUGS (2021)
Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial
Aditi R. Saxena et al.
NATURE MEDICINE (2021)
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing
Michael O. Frederick et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2021)
Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
Michishige Terasaki et al.
BIOMEDICINES (2021)
IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study
Linong Ji et al.
ECLINICALMEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Jennifer M. Trujillo et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2021)
Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study
Maria Alba et al.
CLINICAL OBESITY (2021)
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Brian Finan et al.
DIABETES (2020)
Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic GiuCreERT2; ROSA26-eYFP mice
Dipak Sarnobat et al.
PEPTIDES (2020)
GIP analogues and the treatment of obesity-diabetes
Clifford J. Bailey
PEPTIDES (2020)
The role of GIP in α-cells and glucagon secretion
Kimberley El et al.
PEPTIDES (2020)
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review
Yusaku Mori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
T cell subsets and functions in atherosclerosis
Ryosuke Saigusa et al.
NATURE REVIEWS CARDIOLOGY (2020)
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials
Subodh Verma et al.
DIABETES OBESITY & METABOLISM (2020)
Outcomes in Bariatric and Metabolic Surgery: an Updated 5-Year Review
A. E. Roth et al.
CURRENT OBESITY REPORTS (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
Olof Eriksson et al.
SCIENTIFIC REPORTS (2020)
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Jonathan E. Campbell
MOLECULAR METABOLISM (2020)
Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals
Jie Cui et al.
LIFE SCIENCES (2020)
Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis
Michelle L. Boland et al.
NATURE METABOLISM (2020)
Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions
Annie Hasib
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES (2020)
Glucagon Receptor Signaling and Glucagon Resistance
Lina Janah et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The incretin system in healthy humans: The role of GIP and GLP-1
Jens Juul Hoist
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Vascular smooth muscle cells in atherosclerosis
Gemma L. Basatemur et al.
NATURE REVIEWS CARDIOLOGY (2019)
Terapias antiinflamatorias para la enfermedad cardiovascular: vías de señalización y mecanismos
Sergio Martínez-Hervás et al.
REVISTA ESPANOLA DE CARDIOLOGIA (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Atherosclerosis
Peter Libby et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Eirini Andrikou et al.
HELLENIC JOURNAL OF CARDIOLOGY (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
Anouar Hafiane
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE (2019)
European Society of Cardiology: Cardiovascular Disease Statistics 2017
Adam Timmis et al.
EUROPEAN HEART JOURNAL (2018)
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study
Philip D. Ambery et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
In Young Choi et al.
DIABETES (2018)
Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates
Ralf Elvert et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi et al.
ENDOCRINE REVIEWS (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt et al.
PEPTIDES (2018)
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation
Florian Kahles et al.
MOLECULAR METABOLISM (2018)
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
T. D. Mueller et al.
PHARMACOLOGICAL REVIEWS (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Andreas Evers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Michael Fralick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall et al.
MOLECULAR METABOLISM (2017)
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus
Christophe Schmitt et al.
DIABETES OBESITY & METABOLISM (2017)
Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects
Agnes Portron et al.
DIABETES OBESITY & METABOLISM (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes
Matthias Tschoep et al.
DIABETES (2017)
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschoep et al.
CELL METABOLISM (2016)
Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
William Herrington et al.
CIRCULATION RESEARCH (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis
Alexandra V. Potekhina et al.
ATHEROSCLEROSIS (2015)
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Julio Rosenstock et al.
CARDIOVASCULAR DIABETOLOGY (2015)
DPP4 in Cardiometabolic Disease Recent Insights From the Laboratory and Clinical Trials of DPP4 Inhibition
Jixin Zhong et al.
CIRCULATION RESEARCH (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Islet α cells and glucagon-critical regulators of energy homeostasis
Jonathan E. Campbell et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia
Joseph Chabenne et al.
MOLECULAR METABOLISM (2014)
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
Vikas K. Bhat et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Adipose Dipeptidyl Peptidase-4 and Obesity Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro
Henrike Sell et al.
DIABETES CARE (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Peptide lipidation stabilizes structure to enhance biological function
Brian P. Ward et al.
MOLECULAR METABOLISM (2013)
Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study
Veena Naik et al.
CARDIOVASCULAR RESEARCH (2012)
Smooth muscle cell phenotypic switching in atherosclerosis
Delphine Gomez et al.
CARDIOVASCULAR RESEARCH (2012)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Incretin hormones as immunomodulators of atherosclerosis
Nuria Alonso et al.
Frontiers in Endocrinology (2012)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Fully Human Monoclonal Antibodies Antagonizing the Glucagon Receptor Improve Glucose Homeostasis in Mice and Monkeys
Hai Yan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)
Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects - A double-blind, randomized, controlled trial
K Wynne et al.
DIABETES (2005)
Share Paper
